Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846614 | 0.80 | LMNA (0.46) | POLA1LMNATHRBMTORMDM2 | |
| SCHEMBL9868819 | 0.80 | POLA1 (0.44) | POLA1LMNATHRBMTORMDM2 | |
| SCHEMBL28645147 | 0.79 | LMNA (0.46) | POLA1LMNATHRBMTORMDM2 | |
| SCHEMBL31070840 | 0.79 | LMNA (0.49) | POLA1LMNATHRBMTORMDM2 | |
| SCHEMBL8604152 | 0.79 | LMNA (0.45) | POLA1LMNATHRBMTORMDM2 | |
| SCHEMBL6060585 | 0.79 | LMNA (0.45) | POLA1LMNATHRBMTORMDM2 | |
| SCHEMBL7775032 | 0.78 | LMNA (0.48) | POLA1LMNATHRBMTORMDM2 | |
| Guanidine SCHEMBL28644548 | 0.78 | LMNA (0.43) | POLA1LMNATHRBMTORMDM2 | |
| SCHEMBL25407209 | 0.78 | LMNA (0.44) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL15239320 | 0.77 | LMNA (0.47) | POLA1LMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050509-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2024-02-15 | — | — | US | disclosed |
| US-20210228672-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2021-07-29 | — | — | US | disclosed |
| US-10918687-B2 | Kava derived therapeutic compounds and methods of use thereof | KUALITY HERBCEUTICS LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200261529-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200255395-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2020-08-13 | — | — | US | disclosed |
| US-10624943-B2 | Kava derived therapeutic compounds and methods of use thereof | Kuality Herbceutics, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-10584108-B2 | Therapeutic compounds and methods of use thereof | KUALITY HERBCEUTICS LLC (US) | 2020-03-10 | — | — | US | disclosed |
| US-20180134679-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2018-05-17 | — | — | US | disclosed |
| WO-2016179587-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160279184-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2016-09-29 | — | — | US | disclosed |
| EP-3068416-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Kuality Herbceutics LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015070226-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134679-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NQO1, VHL, XIAP | POLA1 4048/4885LMNA 1634/4885THRB 3611/4885 |
| US-20210228672-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KLK5, KLK4, KLK2 | POLA1 2538/4885LMNA 1125/4885THRB 3035/4885 |
| US-20200255395-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NQO1, VHL, XIAP | POLA1 4048/4885LMNA 1634/4885THRB 3611/4885 |
| US-20200261529-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KLK5, KLK4, KLK2 | POLA1 2538/4885LMNA 1125/4885THRB 3035/4885 |
| US-10918687-B2 | Kava derived therapeutic compounds and methods of use thereof | KLK5, KLK4, KLK2 | POLA1 2538/4885LMNA 1125/4885THRB 3035/4885 |
| US-20240050509-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KLK5, KLK4, KLK2 | POLA1 2538/4885LMNA 1125/4885THRB 3035/4885 |
| US-10584108-B2 | Therapeutic compounds and methods of use thereof | NQO1, VHL, XIAP | POLA1 4048/4885LMNA 1634/4885THRB 3611/4885 |
| US-20160279184-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KLK5, KLK4, KLK2 | POLA1 2538/4885LMNA 1125/4885THRB 3035/4885 |
| US-10624943-B2 | Kava derived therapeutic compounds and methods of use thereof | KLK5, KLK4, KLK2 | POLA1 2538/4885LMNA 1125/4885THRB 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.